"Breaking: Exciting RX Product Updates Unveiled in September 2023"
In September 2023, several pharmaceutical products received FDA approval. Nirsevimab-alip (Beyfortus) by AstraZeneca is a monoclonal antibody that protects neonates and infants from respiratory syncytial virus (RSV). Remdesivir (Veklury) by Gilead Sciences is now approved for COVID-19 patients with severe renal impairment. Inclisiran (Leqvio) by Novartis received an expanded label to treat elevated LDL cholesterol in patients with comorbidities. Lecanemab-irmb (Leqembi) by Eisai Inc and Biogen Inc is now fully approved to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia.